Journals / Eurasian Journal of Medicine and Oncology / 2020 / Cilt: 4 - Sayı: 3

Hydroxychloroquine as Potent Inhibitor of COVID -19 Main Protease: Grid Based Docking Approach

Pages
219–226
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present study reveals that Hydroxychloroquine has good binding affinity with COVID-19 protease and thus can be used as prophylaxis and therapeutic treatment for corona patient.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Corona virus (COVID-19) is an enveloped RNA virus that is diversely originate in humans and wildlife.
📊
Key Findings & Data:As of March 26, 2020, there have been 462.684 confirmed cases globally, and 20.834 deaths have been registered.
💡
Conclusion & Impact:The present study reveals that Hydroxychloroquine has good binding affinity with COVID-19 protease and thus can be used as prophylaxis and therapeutic treatment for corona patient.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: Corona virus (COVID-19) is an enveloped RNA virus that is diversely originate in humans and wildlife. A total of six species have been identified to cause disease in humans. Viral infections play a vital role in human diseases, and recent outbreaks is the arrival globally in form of novel corona. The SS-RNA virus from the enveloped corona virus family caused SARS (Severe acute respiratory syndrome) which is life threatening viral infection. The spreading of infection is rapid in many countries of the world. As of March 26, 2020, there have been 462.684 confirmed cases globally, and 20.834 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods. Methods: In the present research an attempt had been made to find new COVID-19 main protease inhibitor by molecular docking approach. Grid based docking approach has been selected to find out the binding using VLife MDS software. The 2D structure of the compounds were built and then converted into the 3D then energetically minimizedup to the rms gradient of 0.01 using Merck Molecular Force Field (MMFF). By using cavitydetermination option, cavities of enzyme were determined. Cavity no.1 was selected for docking. The active site for docking was defined as all atoms within 5A˚ radius. Results: Hydroxychloroquine is a slow acting antirheumatic drug. The worth of hydroxychloroquine is analogous to that reported for other disease modifying anti-rheumatic drugs. The docking score obtained had been -4.308880 and number of receptor atoms was 77 while number of ligand atoms was 20 which shows that hydroxychloroquine binds effectively with Covid-19 protease. Conclusion: Hydroxychloroquine was taken as drug which follows Lippinski’s rule of five, thus having very good drug score as well as drug likeness score. The present study reveals that Hydroxychloroquine has good binding affinity with COVID-19 protease and thus can be used as prophylaxis and therapeutic treatment for corona patient.

🔖

Cite This Article

MALİK, J. K., SONİ, H., SHARMA, S., SARANKAR, S. (2020). Hydroxychloroquine as Potent Inhibitor of COVID -19 Main Protease: Grid Based Docking Approach. Eurasian Journal of Medicine and Oncology, Cilt: 4 - Sayı: 3, 219–226. https://ajindex.com/articles/124577

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Amit Kumar, H. Soni. Epidemiology of Novel Corona Virus (Covid-19): A Review. Journal of Clinical/Pharmaco-Epidemiology Research. 2020.2(2);5-13
  2. Gopal Samy B & Lawrence Xavier. Molecular Docking Studies on Antiviral Drugs for SARS. ternational Journal of Advanced Research in Computer Science and Software Engineering 5 (3), March- 2015, 75
  3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012; 367: 1814– 20
  4. Anthony R. Fehr and Stanley Perlman. Coronaviruses: An Overview of Their Replication and Pathogenesis. Methods Mol Biol. 2016;1. 5.
  5. Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARSCoV-1. N Engl J Med 2020
  6. Alaa Badaw etal. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases. 2016. 49;129
  7. Malik Jitender, Corona: A Review on Current Clinical Sympathetic, Scholars Journal of Applied Medical Sciences, March 2020, Vol 8(3), 1054-1061. 9. https://www.cdc.gov/coronavirus/2019-ncov/prepare/prevention.html 10.
  8. K Pavelka JR et al Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens. Annals of the Rheumatic Diseases 1989; 48: 542-546. 12. fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl. 13. www.vlifesciences.com 14. www.rcsb.org